Hypothesis

We hypothesize that aged hematopoietic stem cells (HSCs) produce exosomes with a distinct lipid and protein profile that directly induces senescence in peripheral tissues, and that re‑programming the exosome cargo of these HSCs to a youthful phenotype will attenuate systemic inflammaging and extend healthspan independent of other interventions.

Mechanistic Rationale

• Age‑associated myeloid skewing of HSCs increases output of granulocyte‑monocyte progenitors that secrete exosomes enriched in ceramide‑rich lipid rafts and SASP mediators (IL‑6, IL‑1β, MMP‑9) [3].
• These vesicles fuse with recipient cells, delivering pro‑senescent miRNAs (miR‑34a, miR‑146a) and oxidized phospholipids that activate NF‑κB and p38 MAPK pathways, triggering a secondary senescence cascade.
• The resulting senescence amplifies local inflammaging, which feeds back to HSCs via circulating IL‑6, reinforcing myeloid bias—a self‑reinforcing loop.

Testable Predictions

1. Exosomes isolated from myeloid‑biased HSCs of old mice will induce senescence markers (p16^INK4a^, SA‑β‑gal, γH2AX) in young fibroblasts and endothelial cells at a higher rate than exosomes from lymphoid‑balanced HSCs.
2. Proteomic and lipidomic profiling will reveal a signature increase in ceramide, phosphatidylserine, and specific SASP proteins in aged‑HSC exosomes versus young‑HSC exosomes.
3. In vivo injection of young‑HSC‑derived exosomes into aged mice will reduce circulating IL‑6/TNF‑α, lower tissue p16^INK4a^ burden, and improve functional readouts (grip strength, treadmill endurance) within 4 weeks.
4. Genetic or pharmacological perturbation of exosome biogenesis in HSCs (e.g., conditional knockout of Rab27a or neutral sphingomyelinase 2) will blunt the aging‑associated exosome phenotype and delay onset of inflammaging markers.

Experimental Design

• Donor mice: Young (3 mo) and old (24 mo) C57BL/6; isolate HSCs via lineage‑negative Sca1^+cKit^+ sorting.
• Exosome isolation: Differential ultracentrifugation followed by size‑exclusion chromatography; quantify particle count and size by NTA.
• In vitro assays: Treat young NIH‑3T3 fibroblasts and HUVECs with equal exosome doses (1 × 10^9 particles/ml) for 48 h; assess senescence via flow cytometry for p16^INK4a^ and SA‑β‑gal activity.
• Omics: LC‑MS/MS for protein cargo; shotgun lipidomics for ceramide species; small‑RNA sequencing for miRNA payload.
• In vivo intervention: Tail‑vein injection of young‑HSC exosomes (2 × 10^10 particles) twice weekly for 4 weeks into old mice; controls receive PBS or old‑HSC exosomes.
• Readouts: Plasma cytokine multiplex, histology of liver/kidney for p16^INK4a^, functional assays, and survival monitoring.

Falsifiability

If exosomes from aged HSCs fail to induce senescence in vitro, or if young‑HSC exosome administration does not reduce systemic inflammation or tissue senescence in vivo, the hypothesis would be refuted. Conversely, confirmation would support the notion that immune‑derived exosome cargo is a proximate driver of aging, suggesting that re‑programming HSC exosome biogenesis could be a singular lever to slow aging.